Japanese drugmaker Takeda recently announced refunds to 340B covered entities for 28 drugs, including one of its top-selling attention-deficit medications. [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.